Zacks Investment Research Lowers Medicure Inc. (MCUJF) to Hold
Zacks Investment Research cut shares of Medicure Inc. (OTCMKTS:MCUJF) from a buy rating to a hold rating in a report released on Saturday.
According to Zacks, “Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. “
Separately, ValuEngine upgraded Medicure from a buy rating to a strong-buy rating in a research report on Saturday, June 17th.
Shares of Medicure (MCUJF) opened at 6.15 on Friday. Medicure has a 1-year low of $4.11 and a 1-year high of $7.96. The firm’s 50-day moving average price is $6.39 and its 200 day moving average price is $6.26. The stock has a market capitalization of $96.14 million, a price-to-earnings ratio of 5.71 and a beta of 0.55.
Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related stocks with our FREE daily email newsletter.